Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Toshitaka Okuno"'
Autor:
Nina Odan, Yuichiro Kikawa, Hajime Matsumoto, Junya Minohata, Hirofumi Suwa, Takashi Hashimoto, Toshitaka Okuno, Masaru Miyashita, Masaru Saito, Kazuhiko Yamagami, Shintaro Takao
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 14 (2020)
Background: Clinical studies have shown that palbociclib improves progression-free survival in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) patients with advanced breast cancer (ABC). However, there
Externí odkaz:
https://doaj.org/article/e7749095d95342aab4ae9a2a27a24e9c
Autor:
Yuri Kimura, Norio Masumoto, Sadako Akashi-Tanaka, Kayo Fukui, Midori Noma, Aya Nagata, Takashi Nakamura, Hiroaki Shima, Toshitaka Okuno, Akari Murakami, Yoshiaki Kamei, Shogo Nakano, Koji Arihiro
Publikováno v:
Cancer Research. 83:P3-04
Background: Tumor-infiltrating lymphocytes (TILs) are a useful prognostic factor and predictive biomarker of neoadjuvant chemotherapy treatment response for breast cancer, especially in human epidermal growth factor receptor type 2 (HER2)-positive br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21bc6f7da8ce6a57fc938facbf59bb8d
https://doi.org/10.1158/1538-7445.sabcs22-p3-04-10
https://doi.org/10.1158/1538-7445.sabcs22-p3-04-10
Autor:
Hiroyasu Yamashiro, Tetsuya Taguchi, Nobuko Ogura, Tomoharu Sugie, Masakazu Toi, Ichiro Nakayama, Hiroshi Ishiguro, Shigeru Tsuyuki, Yuri Fujimoto, Tatsuji Kato, Sachiko Takahara, Hiroshi Yoshibayashi, Masahiro Takada, Tatsuo Kagimura, Yoshio Moriguchi, Kazuhiko Yamagami, Rie Yasuoka, Takeshi Kotake, Hirofumi Suwa, Yuichiro Kikawa, Toshitaka Okuno
Publikováno v:
Cancer Research. 81:PS13-31
BackgroundEribulin (E) is a chemotherapeutic drug that prolongs overall survival (OS) of patients with HER2-negative advanced or metastatic breast cancer (AMBC), mainly in multi-line chemotherapy (ChT) or later. However, the effectiveness and optimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a344127d16b868c85ad3b61db4f9c11
https://doi.org/10.1158/1538-7445.sabcs20-ps13-31
https://doi.org/10.1158/1538-7445.sabcs20-ps13-31
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 82:690-696
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::421fe8919a3578bcfca56037222c5f88
https://doi.org/10.3919/jjsa.82.690
https://doi.org/10.3919/jjsa.82.690
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 82:2107-2112
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d684c84edb62c947b01bbaad96e3543
https://doi.org/10.3919/jjsa.82.2107
https://doi.org/10.3919/jjsa.82.2107
Autor:
Shintaro Takao, Seishi Kono, Masaru Miyashita, Muneharu Konishi, Ikuo Kokufu, Hirofumi Suwa, Koushiro Kitatsuji, Yutaka Konishi, Isao Sakita, Masayuki Nishino, K Yamagami, Hidefumi Nishikawa, Masahiro Kishimoto, Keisuke Miyauchi, Takashi Matsumoto, Toshitaka Okuno, Akihiro Miya, Koushi Oh, Masashi Baba, Kazuyuki Wakita, Toshiharu Hidaka, Takashi Hashimoto, Yoko Sakoda, Shigetoshi Ichii, Yasuo Miyoshi, Junya Minohata, Yuichiro Kikawa, Chiyomi Egawa
Publikováno v:
Cancer Research. 80:P5-12
Background Five-year adjuvant treatment with aromatase inhibitors is a standard treatment for postmenopausal women with estrogen receptor-positive breast cancer. However, aromatase inhibitor-related adverse events, including joint and vasomotor sympt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0f0dda4eab31d3ae4987c4c8337ee5f
https://doi.org/10.1158/1538-7445.sabcs19-p5-12-07
https://doi.org/10.1158/1538-7445.sabcs19-p5-12-07
Autor:
Yuichiro Kikawa, Takeshi Kotake, Shigeru Tsuyuki, Yookija Kang, Sachiko Takahara, Yuri Fujimoto, Hiroyasu Yamashiro, Hiroshi Yoshibayashi, Masahiro Takada, Rie Yasuoka, Katsuhiko Nakatsukasa, Kazuhiko Yamagami, Hirofumi Suwa, Toshitaka Okuno, Ichiro Nakayama, Tatsushi Kato, Nobuko Ogura, Yoshio Moriguchi, Hiroshi Ishiguro, Tatsuo Kagimura, Tetsuya Taguchi, Tomoharu Sugie, Masakazu Toi
Publikováno v:
Breast cancer (Tokyo, Japan). 29(5)
The optimal positioning of eribulin treatment remains unclear. This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d16e5c2cd0d16e662ed9a8529f8fd4e3
https://pubmed.ncbi.nlm.nih.gov/35460066
https://pubmed.ncbi.nlm.nih.gov/35460066
Autor:
Shigeru Tsuyuki, Hiroshi Yoshibayashi, Sachiko Takahara, Nobuko Ogura, Akira Yamauchi, Toshitaka Okuno, Takashi Inamoto, Satoru Tanaka, Yuichiro Kikawa, Takashi Hashimoto, Haruko Takuwa, Tomoharu Sugie, Yutaka Mizuno, Kazuhiko Yamagami, Hironori Kato, Hiroyasu Yamashiro, Tatsushi Kato, Toshiro Katayama
Publikováno v:
The Breast. 47:22-27
Background We have developed a surgical glove (SG)-compression therapy and reported that this method significantly reduced the overall occurrence of grade 2 or higher nanoparticle albumin-bound-paclitaxel (nab-PTX)-induced peripheral neuropathy (PN)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1507ab856f769c81d95cd500c06ab96a
https://doi.org/10.1016/j.breast.2019.06.008
https://doi.org/10.1016/j.breast.2019.06.008
Autor:
Masaru Miyashita, Michiko Imamura, Kazuhiko Yamagami, Mayuko Miki, Toshitaka Okuno, Shintaro Takao, Hirofumi Suwa, Muneharu Konishi, Yasuo Miyoshi, Yasushi Shigeoka, Koichi Hirokaga, Keiko Murase, Hirokazu Tanino, Ayako Yanai
Publikováno v:
Anticancer research. 41(6)
Background/aim S-1, a 5-fluorouracil(5-FU) oral anti-cancer drug, has been traditionally used with a schedule of 4-week oral administration followed by 2-week rest for breast cancer treatment. We, herein, aimed to investigate the clinical efficacy an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152b6e30c000c823866e19182272b04a
https://pubmed.ncbi.nlm.nih.gov/34083305
https://pubmed.ncbi.nlm.nih.gov/34083305
Autor:
Nobuko Ogura, Masakazu Toi, Hiroyasu Yamashiro, Yuichiro Kikawa, Yookija Kang, Katsuhiko Nakatsukasa, Hiroshi Ishiguro, Hiroshi Yoshibayashi, Masahiro Takada, Tatsuji Kato, Sachiko Takahara, Hirofumi Suwa, Tatsuo Kagimura, Yoshio Moriguchi, Tomoharu Sugie, Kazuhiko Yamagami, Rie Yasuoka, Yuri Fujimoto, Tetsuya Taguchi, Toshitaka Okuno, Ichiro Nakayama, Takeshi Kotake, Shigeru Tsuyuki
PurposeTo investigate the survival impact of eribulin use in first-line and second-line chemotherapy for patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical setting. MethodsThis multi-institutional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a450129b8825cb46485a94ad1cbbc03e
https://doi.org/10.21203/rs.3.rs-412075/v1
https://doi.org/10.21203/rs.3.rs-412075/v1
